|
|
|
|
|
|
|
|
|
|
|
|
|
11.02.26 - 12:48
|
Chimera Increases First Quarter 2026 Common Stock Dividend to $0.45 and Declares First Quarter 2026 Preferred Stock Dividends (Business Wire)
|
|
|
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.45 PER SHARE OF COMMON STOCK
BOARD EXPECTS CHIMERA TO MAINTAIN A QUARTERLY DIVIDEND OF $0.45 PER COMMON SHARE FOR THE REMAINING THREE QUARTERS OF 2026
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.50 PER SHARE OF 8.00% SERIES A CUMULATIVE REDEEMABLE PREFERRED STOCK
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.6078 PER SHARE OF 8.00% SERIES B FIXED-TO-FLOATING RATE CUMULATIVE REDEEMABLE PREFERRED STOCK
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.5423 PER SHARE OF 7.75% SERIES C FIXED-TO-FLOATING RATE CUMULATIVE REDEEMABLE PREFERRED STOCK
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.5820 PER SHARE OF 8.00% SERIES D FIXED-TO-FLOATING RATE CUMULATIVE REDEEMABLE PREFERRED STOCK
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Chimera Investment Corporation (“Chimera”) announced the declaration of its first quarter cash dividend of $0.45 per common share, an increase from its fourth quarter 2025 cash dividend of $0.37. The dividend is paya...
|
|
|
11.02.26 - 12:48
|
CHIMERA INVESTMENT CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2025 EARNINGS (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE:CIM) today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Fourth Quarter 2025 Financial Highlights:
GAAP NET INCOME OF $7 MILLION, OR $0.08 PER DILUTED COMMON SHARE FOR THE QUARTER ENDED DECEMBER 31, 2025.
EARNINGS AVAILABLE FOR DISTRIBUTION(1) OF $45 MILLION, OR $0.53 PER ADJUSTED DILUTED COMMON SHARE.
GAAP BOOK VALUE OF $19.70 PER COMMON SHARE AT DECEMBER 31, 2025, AND ECONOMIC RETURN(2) OF (0.9)% FOR THE QUARTER ENDED DECEMBER 31, 2025.
Full Year 2025 Financial Highlights:
GAAP NET INCOME OF $144 MILLION, OR $1.72 PER DILUTED COMMON SHARE FOR THE YEAR ENDED DECEMBER 31, 2025.
EARNINGS AVAILABLE FOR DISTRIBUTION(1) OF $141 MILLION, OR $1.68 PER ADJUSTED DILUTED COMMON SHARE.
ECONOMIC RETURN(2) OF 7.4% FOR THE YEAR ENDED DECEMBER 31, 2025.
“We're extremely pleased with our fourth-quarter results and the meaningful increase in our dividend,” said Phillip J. Kardis II, President and CEO. “W...
|
|
|
|
|
|
|
28.01.26 - 22:18
|
Chimera Investment Corporation Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call Date (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE: CIM) (the "Company") announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, February 11, 2026, prior to 7:00 a.m. Eastern Standard Time (EST). The Company will host a conference call and live audio webcast to discuss the results on Wednesday, February 11, 2026, at 8:30 a.m. EST.
Call-in Number:
U.S. Toll Free: (866) 604-1613
International: (201) 689-7810
Webcast: https://www.chimerareit.com/news-events/ir-calendar
Conference Call Replay:
U.S. Toll Free: (877) 660-6853
International: (201) 612-7415
Conference ID: 13757751
A replay of this call can be accessed through Wednesday, February 25, 2026.
If you would like to be added to the e-mail distribution list, please visit www.chimerareit.com, click on News & Events, and complete the email notification form.
About Chimera Investment Corporation
Chimera is a publicly traded real estate investment trust, or REIT, whos...
|
|
|
29.12.25 - 14:06
|
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies (Business Wire)
|
|
|
Acquisition brings an advanced, highly differentiated treatment for prostate cancer, strengthening Johnson & Johnson's longstanding commitment to innovation in the disease
Lead asset demonstrates potential to overcome key resistance pathways in prostate cancer through targeted tumor cell eradicationNEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash.
“This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “We are excited...
|
|
|
18.12.25 - 22:36
|
Chimera Declares Fourth Quarter 2025 Common Stock Dividend (Business Wire)
|
|
|
BOARD DECLARES FOURTH QUARTER 2025 DIVIDEND OF $0.37 PER SHARE OF COMMON STOCK
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Chimera Investment Corporation announced the declaration of its fourth quarter cash dividend of $0.37 per common share. The dividend is payable on January 30, 2026 to common stockholders of record on December 31, 2025. The ex-dividend date is December 31, 2025.
About Chimera Investment Corporation
Chimera is a publicly traded real estate investment trust, or REIT, whose principal business objective is to provide attractive risk-adjusted returns and distributable income through investment performance linked to mortgage credit fundamentals. Through its mortgage lending, investment management, and advisory services platforms, Chimera operates as a fully integrated mortgage business that originates, manages, and invests in a diversified range of mortgage assets. Chimera invests, directly or indirectly, generally on a levered basis across a spectrum of mortgage assets, including r...
|
|
|
17.11.25 - 14:03
|
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics (Business Wire)
|
|
|
Acquisition provides highly differentiated clinical-stage treatment for prostate cancer, building on Johnson & Johnson's nearly two decades of innovation in the disease area
Lead asset shows potential to overcome common types of resistance to treatment in prostate cancer with a precision tumor cell-killing approach
Includes novel technology platform capable of developing the next generation of highly targeted oral treatments for multiple solid tumors, including breast and lung cancersNEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, subject to antitrust clearance a...
|
|
|
10.11.25 - 14:33
|
Chimera Integrations Expands Into Rochester with New Leadership Team and Regional Headquarters (Business Wire)
|
|
|
ROCHESTER, N.Y.--(BUSINESS WIRE)--Chimera Integrations, a nationally recognized leader in security technology integration, is proud to announce the opening of its newest regional office located at 2510 Chili Avenue, Suite 1, Rochester, NY 14624. This expansion marks a strategic move to bring Chimera's innovative, community-first approach to the entire Finger Lakes and Western New York region, supported by a deeply experienced local leadership team.
The Rochester team is led by Ken Laubacher, Sebastian Gimeli, and Jacob Rinck - three industry veterans who bring over 60 years of combined experience in security, project execution, and customer service.
“After 50 years of living and working in this community I'm excited to help build something meaningful here,” said Ken Laubacher, the new Regional Director. “We're not just selling technology. We're creating partnerships and designing safer environments where people can live, work, and learn.”
Sebastian Gimeli, Project Manager, brings a dual backgr...
|
|
|
|
|
06.11.25 - 12:48
|
CHIMERA INVESTMENT CORPORATION REPORTS 3RD QUARTER 2025 EARNINGS (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE:CIM) today announced its financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights:
GAAP NET LOSS OF $0.27 AND GAAP NET INCOME OF $1.67 PER DILUTED COMMON SHARE FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025, RESPECTIVELY.
EARNINGS AVAILABLE FOR DISTRIBUTION(1) OF $0.37 PER ADJUSTED DILUTED COMMON SHARE.
GAAP BOOK VALUE OF $20.24 PER COMMON SHARE AT SEPTEMBER 30, 2025, AND ECONOMIC RETURN(2) OF (1.4)% AND 8.3% FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025, RESPECTIVELY.
COMPLETED THE ACQUISITION OF HOMEXPRESS ON OCTOBER 1, 2025 FOR $240 MILLION IN CASH, COMPRISED OF AN ESTIMATED ADJUSTED BOOK VALUE OF $120 MILLION (SUBJECT TO CERTAIN POST-CLOSING ADJUSTMENTS) AND A PREMIUM OF $120 MILLION, PLUS THE ISSUANCE OF 2,077,151 SHARES OF OUR COMMON STOCK.
“The third quarter marked an important transition in the history of our business as we moved to cash in preparation for the acq...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
